Skip to main content
. Author manuscript; available in PMC: 2017 Jan 1.
Published in final edited form as: Am J Transplant. 2015 Jul 30;16(1):221–234. doi: 10.1111/ajt.13416

Figure 12. PBMC proliferation response to mitogens and a recall antigen.

Figure 12

A. Note that pre-operatively there were no differences in reactivity between the Tol and non-Tol groups (with ESRD) versus normal laboratory volunteers (Patient #8 was still considered tolerant since the assays were performed between 3 and 5 years post-operatively (see Table 1 and Figure 3B). The pre-operative samples analyzed included patient #2, #5, #6, #9, #11, and #13 in the Tol group. The non-Tol group included #1, #3, #4, #8, #10, #12, #16, and #18. B. Note that there was no difference between the Tol and non-Tol groups post-operatively with each group having significantly lower responses than normal laboratory volunteers (*, p=0.03 and 0.02, at the base of the figure). This was despite all Tol recipients being IS-free for over one year. In the Tol group, the assays were performed on patient #2, #6, #9, #11, and #13. In the non-Tol group the assays were performed on patients #1, #3, #4, #8, and #12, all on IS for greater than one year. A log scale was used to emphasize the tetanus response differences vs normals.